Meeting
2020 Genitourinary Cancers Symposium
Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC).
Authors
Jens Bedke
Department of Urology, University of Tuebingen, Tuebingen, Germany
Jens Bedke , Axel Stuart Merseburger , Yohann Loriot , Daniel Castellano , Ernest Choy , Ignacio Duran , Jonathan E. Rosenberg , Daniel Peter Petrylak , Robert Dreicer , Jose Luis Perez-Gracia , Jean H. Hoffman-Censits , Michiel Simon Van Der Heijden , Viraj Degaonkar , Lars Thiebach , Sabine de Ducla , Simon Fear , Thomas Powles , Cora N. Sternberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02108652; NCT02302807; NCT02928406
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 492)
Abstract #
492
Poster Bd #
H15
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Impact of renal impairment on clinical outcomes in patients (pts) with locally advanced or metastatic (LA/M) urinary tract carcinoma (UTC) treated with atezolizumab (atezo): Analysis of the international SAUL study.
First Author: Margitta Retz
Poster
2023 ASCO Annual Meeting
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
First Author: Kazuomi Ueshima
Poster
2020 ASCO Virtual Scientific Program
Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.
First Author: Daniel Castellano
Poster
2018 ASCO Annual Meeting
Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.
First Author: Arjun Vasant Balar